Naperville, IL -- (SBWIRE) -- 08/15/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Peptic Ulcer Drugs Market 2014-2018 market report to its offering
About Peptic Ulcer and Drugs Used for the Treatment
A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and enzymes in these organs. The symptoms of peptic ulcers are pain in the abdomen, nausea, vomiting, and bloated stomach. The major symptoms include bleeding from the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. Peptic ulcers are caused mainly by a Helicobacter pylori infection followed by the overuse of OTC NSAIDs such as Naproxen, Aspirin and Ibuprofen. Peptic ulcers can be of two types based on the site of the ulcer: gastric ulcer and duodenal ulcer.
Analysts forecast the Global Peptic Ulcer Drugs market to grow at a CAGR of 2.9 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Peptic Ulcer Drugs market for the period 20142018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of peptic ulcers that are available in the market.
Global Peptic Ulcer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Peptic Ulcer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
EMEA
APAC
Key Vendors
AstraZeneca plc
Eisai Co. Ltd.
Daewoong Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Other Prominent Vendors
Daiichi Sankyo
Dr. Reddy's Laboratories
Eumedica
Ferring Pharmaceuticals
Horizon Pharma
Johnson and Johnson
Merck Sharp and Dohme
Otsuka Holdings
Pfizer
PharmaKing
Pozen
Rottapharm Madaus
Taiho Pharmaceutical
Zeria Pharmaceutical
Zuventus Healthcare
Market Driver
Increased Incidence of H. pylori Infections.
For a full, detailed list, view our report.
Market Challenge
Adverse Effect of PPIs.
For a full, detailed list, view our report.
Market Trend
Use of Combination Drugs.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Companies Mentioned
AstraZeneca plc, Eisai Co. Ltd., Daewoong Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo, Dr. Reddy's Laboratories, Eumedica, Ferring Pharmaceuticals, Horizon Pharma, Johnson and Johnson, Merck Sharp and Dohme, Otsuka Holdings, Pfizer, PharmaKing, Pozen, Rottapharm Madaus, Taiho Pharmaceutical, Zeria Pharmaceutical and Zuventus Healthcare
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/167228/global-peptic-ulcer-drugs-market-2014-2018-.html
Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604